AEON Biopharma, Inc. (NYSE American: AEON) announced its financial results for the year ended December 31, 2025, highlighting significant advancements in its ABP-450 biosimilar program. The company reported cash and cash equivalents of $3.0 million as of December 31, 2025, which does not include an additional $4.2 million from a PIPE financing completed in January 2026. This funding is expected to support operations into the third quarter of 2026. The company also reported a net loss of $39.2 million for the year, reflecting ongoing investments in research and development as well as operational expenses. Notably, AEON received positive feedback from the FDA following a Biological Product Development (BPD) Type 2a meeting, which provided a clear framework for advancing its comparative analytical plan for ABP-450, a proposed biosimilar to BOTOX. The FDA's constructive feedback is expected to facilitate the completion of the majority of AEON's analytical comparability program in 2026. Additionally, the company strengthened its balance sheet through a $6 million PIPE financing and a note exchange with Daewoong Pharmaceutical, reducing outstanding debt by over 90%. AEON appointed John Bencich as Chief Financial Officer, bringing extensive experience in capital markets and strategic leadership. The company is optimistic about its path forward, aiming for full-label U.S. market entry for ABP-450, supported by strong foundational biosimilarity data. With these developments, AEON is well-positioned to execute its next stage of development and enhance its market presence in the therapeutic neurotoxin sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.